Pharsight

Mytesi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7341744 NAPO PHARMS INC Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer
Jun, 2022

(1 year, 9 months ago)

US9585868 NAPO PHARMS INC Methods and compositions for treating HIV-associated diarrhea
Oct, 2031

(7 years from now)

US8962680 NAPO PHARMS INC Methods and compositions for treating HIV-associated diarrhea
Oct, 2031

(7 years from now)

Mytesi is owned by Napo Pharms Inc.

Mytesi contains Crofelemer.

Mytesi has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Mytesi are:

  • US7341744

Mytesi was authorised for market use on 31 December, 2012.

Mytesi is available in tablet, delayed release;oral dosage forms.

Mytesi can be used as symptomatic relief of non-infectious diarrhea.

The generics of Mytesi are possible to be released after 31 October, 2031.

Drugs and Companies using CROFELEMER ingredient

Market Authorisation Date: 31 December, 2012

Treatment: Symptomatic relief of non-infectious diarrhea

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage

MYTESI family patents

Family Patents